
SGRY$23.20▲ 0.1%Surgery Partners' board kept its $25 buyer over a $28 proposal it called slower to close
HealthSpan Partners raised its buyout of Surgery Partners to $25 a share after an unnamed bidder proposed $28, the company said Nov. 9. The amendment also adds payments for delay and drops a limit on HealthSpan's antitrust obligations.
KeyVex News··5 min readFact-checked against 11 public records
KeyVex News··5 min readFact-checked against 11 public records
SGRY$23.20▲ 0.1%Close, Nov. 6. Prices from Tiingo.Follow-upThis story follows our Oct. 26 report, Surgery Partners: $25.75 a share turned down, $23.50 agreed. Adds the Nov. 8 amendment raising the price to $25 and the $28 proposal from another bidder that the board did not take.
The short versionTap to readTap to close
- When a company agrees to sell, a higher offer can still win. Before holders vote, Surgery Partners can switch only to one it finds superior, and then owes HealthSpan a $149.1 million fee.
- An unnamed bidder made a proposal Nov. 3 and updated it Nov. 8 to $28 a share; it is not binding. A board committee found it not superior. The company cited a slower expected close.
- HealthSpan raised to $25. The amendment drops a limit on the antitrust remedies it must accept. If holders approve but closing slips past March 1, 2027, it pays them monthly.
- Even with every payment, HealthSpan's price tops out at $26.61, below $28, the company says. Bain Capital, owner of about 39%, trades its shares for a stake in the buyer and gets no payments.
- Next: a proxy statement, sent before a vote, and a going-private disclosure. The vote needs a majority of all shares and of votes cast by holders other than Bain, the buyer, directors and officers.
The raise: Surgery Partners is sticking with its buyer. HealthSpan Partners, an affiliate of the nonprofit hospital system Bon Secours Mercy Health, raised its offer to $25 a share in cash from $23.50, the company said before the market opened on Nov. 9.8-KRelease
The rival: The other bidder made its proposal Nov. 3 and updated it Nov. 8. As updated, it offers $28 a share in cash. It is not binding, and the company has not named the bidder or said whether it has responded.Release A committee of independent directors found it was not a "Superior Proposal." Under the merger agreement, that test counts the conditions and likelihood of closing, and any changes HealthSpan offers.Merger agreement The board and the committee said they weighed that the rival deal would be expected to take "materially longer" to close, or may not close. They also cited regulatory risk and protections the proposal lacked.Release
Why it matters: The rival proposal is $3 a share higher and not binding. HealthSpan's amendment adds terms about closing. It must accept antitrust remedies without the old limit, and pays other holders for each month of delay after March 1, 2027, if holders have approved.8-K Even with every payment, its price tops out at $26.61, the company says.Release
Surgery Partners' stock and the bidsDaily close, Dec. 2, 2024 to Nov. 6, 2026 ▼ 2.6%Show chartHide chart
What HealthSpan added
The payments are 10% a year on $25, about 20.8 cents a share a month.Amendment Run to Oct. 23, 2027, the outside date the company used, they add up to $1.61, it says.8-KMerger agreement Bain's funds get none of it; they exchange their shares for equity in the buyer.Release
The bigger change is in the antitrust promise. Regulators can ask a buyer to sell assets or accept conditions, called remedies, before they let a deal close. The October agreement let HealthSpan refuse remedies with more than an immaterial effect on HealthSpan, Bon Secours or their affiliates, or a material adverse effect on the combined company. It also made HealthSpan's obligation to close conditional on no approval coming with one.Merger agreement The amendment deletes both.Amendment
The Amendment revises the covenant to remove the materiality limitation on Parent’s obligations to take any and all such mitigating actions.
The fee Surgery Partners would owe HealthSpan, including if it took a better offer, rose to $149.1 million from about $109 million.Amendment8-K If it ends the deal to take one before holders vote, it also repays up to $8.25 million of HealthSpan's expenses.Amendment
What $25 is worth against $28
Proposal, amendment and payments: the Nov. 9 8-K and its exhibits. Bain's bid: its Jan. 27, 2025 letter. Close: Tiingo end-of-day, as traded, via KeyVex.
HealthSpan's most possible price, $26.61, is $1.39 short of $28.Release On the 81.0 million shares Bain does not own, $3 a share comes to about $243 million, by KeyVex's math from the August share count.10-Q13D/A
The stock closed at $23.20 on Nov. 6, the last trading day before the announcement, below the $23.50 deal price.Chart data It had not closed at $25 or higher since Feb. 26, 2025.Chart data At 10:15 a.m. on Nov. 9 it traded at $25.91.KeyVex Reuters reported the shares climbed 12% in morning trading.Reuters
Chief executive Eric Evans said in the release:Release
This transaction provides exceptional value for our stockholders, along with regulatory certainty and a closing expected in the near term.
Who decides
Bain's funds, with about 39% by the company's count, have agreed to vote for HealthSpan, and that agreement "remains in place," the release says.Release It ends if the merger agreement is validly ended, including to take a superior proposal; Bain may sign with that bidder when the company does.Voting agreement
Closing needs a majority of all shares, which Bain's votes help reach. It also needs a majority of the votes cast by holders other than Bain, the buyer and the company's directors and officers.8-K The board recommends a yes vote.Release
The company has weighed a buyout before. In June 2025, a board committee and Bain Capital ended talks on Bain's non-binding $25.75 bid. The committee said the company's prospects as an independent public company "exceeded the value" of it, KeyVex reported on Oct. 26.ReleaseBain letter
Surgery Partners says it will file a proxy statement and a Schedule 13E-3, a going-private disclosure, before the vote.8-K The companies still expect to close in the first quarter of 2027.Release
What to watch
The proxy statement and Schedule 13E-3, which the company says will contain important information about the deal.
When the companies expect to close, if holders and regulators approve.
If holders have approved and the deal has not closed, monthly payments of about 20.8 cents a share begin.
The outside date the company used for the $1.61 maximum.
The paper trail
The filings this story rests on, January 2025 through Nov. 9, 2026, with the time EDGAR accepted each one.
| Filed (ET) | Form | Filer | What it shows |
|---|---|---|---|
| Jan. 28, 2025, 8:49 a.m. | 13D/A | Bain Capital funds | Discloses Bain's $25.75 proposal and attaches its letter. |
| June 17, 2025, 8:03 a.m. | 8-K | Surgery Partners | The committee and Bain end their talks. |
| Oct. 26, 2026, 9:03 a.m. | 8-K | Surgery Partners | The $23.50 merger agreement and Bain's voting agreement. |
| Nov. 9, 2026, 9:15 a.m. | 8-K | Surgery Partners | The amendment to $25, the monthly payments and the $28 proposal. |
Related coverage
Sources
14 sources, 11 of them public records
Public records
- Surgery Partners Inc., Form 8-K: Amendment No. 1 to the merger agreement (Items 1.01, 7.01, 9.01)SEC EDGAR · Nov. 9, 2026
- Surgery Partners Inc., Form 8-K, Exhibit 2.2: Amendment No. 1 to Agreement and Plan of Merger, dated Nov. 8, 2026SEC EDGAR · Nov. 9, 2026
- Surgery Partners Inc., Form 8-K, Exhibit 99.1: "Surgery Partners and HealthSpan Partners Announce Amended Merger Agreement, Following Receipt of Unsolicited Proposal"SEC EDGAR · Nov. 9, 2026
- Surgery Partners Inc., Form 8-K: merger agreement with Spyglass Topco (Items 1.01, 7.01, 9.01)SEC EDGAR · Oct. 26, 2026
- Surgery Partners Inc., Form 8-K, Exhibit 2.1: Agreement and Plan of Merger, dated Oct. 23, 2026SEC EDGAR · Oct. 26, 2026
- Surgery Partners Inc., Form 8-K, Exhibit 10.1: Voting and Support AgreementSEC EDGAR · Oct. 26, 2026
- BCPE Seminole Holdings LP et al., Schedule 13D/A (Amendment No. 9)SEC EDGAR · Jan. 28, 2025
- Bain Capital Private Equity, proposal letter to the Surgery Partners board (13D/A No. 9, Exhibit 12)SEC EDGAR · Jan. 27, 2025
- Surgery Partners Inc., Form 8-K, Exhibit 99.1: "Surgery Partners, Inc. and Bain Capital Conclude Discussions"SEC EDGAR · June 17, 2025
- BCPE Seminole Holdings LP et al., Schedule 13D/A (Amendment No. 11)SEC EDGAR · Oct. 26, 2026
- Surgery Partners Inc., Form 10-Q for the quarter ended June 30, 2026SEC EDGAR · Aug. 10, 2026
Reporting
- "Bon Secours affiliate sweetens bid for Surgery Partners to up to $6 billion" (as syndicated)Reuters · Nov. 9, 2026
Data
- End-of-day prices for SGRY, and for SPY and QQQ on the chart (Tiingo)KeyVex · through Nov. 6, 2026
- Intraday quote for SGRY (Tiingo IEX), 10:15 a.m. ETKeyVex · Nov. 9, 2026
How we got these numbers
- Prices are end-of-day closes as traded, not adjusted for dividends. Every close in the chart's Story range is in its data table. The S&P 500 and Nasdaq 100 lines follow SPY and QQQ, also as traded, rebased to the start of the range shown. The Filings switch shows the filing markers from KeyVex's Surgery Partners stock page, a selection of insider trades, Form 144 notices, 8-Ks and lobbying filings: not every filing, and not only those tied to this story.
- The Nov. 9 price of $25.91 is the last trade on IEX at 10:15 a.m. ET, from KeyVex's intraday quote; it is not a close. The closes at or above $25 and $28 cover every close in KeyVex's SGRY history through Nov. 6, 2026.
- The monthly payment is $0.208333 a share, one-twelfth of 10% of $25, as the amendment states; the company puts the most it can add, through Oct. 23, 2027, at $1.61. The $243 million is 80,971,288 shares (130,918,260 outstanding on Aug. 3, 2026, less Bain's 49,946,972) times $3, or $242.9 million: KeyVex's math, leaving out stock options and other equity awards. The termination fee is $149,101,164.45 in the amendment and was $108,986,842 in the October agreement.
- The header image was generated for KeyVex by an image model. It is an illustration, not a photograph of a Surgery Partners facility.





